WallStSmart

Incannex Healthcare Ltd ADR (IXHL)vsZoetis Inc (ZTS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ZTS leads profitability with a 27.7% profit margin vs 0.0%. ZTS earns a higher WallStSmart Score of 58/100 (C).

IXHL

Avoid

24

out of 100

Grade: F

Growth: 2.7Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -12.72

ZTS

Buy

58

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 6.0Quality: 7.0
Piotroski: 4/9Altman Z: 3.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for IXHL.

ZTSUndervalued (+11.3%)

Margin of Safety

+11.3%

Fair Value

$145.00

Current Price

$72.97

$72.03 discount

UndervaluedFair: $145.00Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IXHL2 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

ZTS5 strengths · Avg: 9.8/10
P/E RatioValuation
12.0x10/10

Attractively priced relative to earnings

Return on EquityProfitability
83.1%10/10

Every $100 of equity generates 83 in profit

Operating MarginProfitability
40.7%10/10

Strong operational efficiency at 40.7%

Altman Z-ScoreHealth
3.1410/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
27.7%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

IXHL4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$39.12M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

ZTS4 concerns · Avg: 3.0/10
Price/BookValuation
9.3x4/10

Trading at 9.3x book value

EPS GrowthGrowth
1.2%4/10

1.2% earnings growth

PEG RatioValuation
7.052/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : IXHL

The strongest argument for IXHL centers on Price/Book, Debt/Equity.

Bull Case : ZTS

The strongest argument for ZTS centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 27.7% and operating margin at 40.7%.

Bear Case : IXHL

The primary concerns for IXHL are EPS Growth, Market Cap, Profit Margin.

Bear Case : ZTS

The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.

Key Dynamics to Monitor

IXHL profiles as a value stock while ZTS is a declining play — different risk/reward profiles.

IXHL carries more volatility with a beta of 2.81 — expect wider price swings.

ZTS is growing revenue faster at -0.2% — sustainability is the question.

ZTS generates stronger free cash flow (538M), providing more financial flexibility.

Bottom Line

ZTS scores higher overall (58/100 vs 24/100), backed by strong 27.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Incannex Healthcare Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Incannex Healthcare Limited is engaged in the research, development and sale of medicinal cannabinoid products in Australia. The company is headquartered in Sydney, Australia.

Visit Website →

Zoetis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.

Visit Website →

Want to dig deeper into these stocks?